VANCOUVER, British Columbia, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) (the "Company"), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that its Board of Directors has authorized a Share Repurchase Program under which the Company may repurchase up to $60.0 million of the Company's outstanding common stock, par value $0.00001 per share. Zymework ...

Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results • Reported $395.9 million in cash resources as of June 30, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027 • Priority Review of the Biologics License Application (BLA) granted for zanidatamab as second-line (2L) treatment for HER2-positive biliary tract cancers (BTC) in the United States with target action date of November 29, 2024 • The European ...

BTIG Virtual Biotechnology Conference: Zymeworks' management will participate in virtual one-on-one meetings and a fireside chat on Tuesday, August 6 at 4:00 pm Eastern Time (ET). Wedbush PacGrow Healthcare Conference: Zymeworks' management will participate a panel discussion titled "ADCs and Old Lace: Antibody Drug Conjugates" taking place on August 14, between 8:45 – 9:25 am ET, and will participate in one-on-one meetings on August 13-14 in New York, NY. VANCOUVER, British Columbia, July 30, 2024 (GLOBE N ...

BTIG Virtual Biotechnology Conference: Zymeworks' management will participate in virtual one-on-one meetings and a fireside chat on Tuesday, August 6 at 4:00 pm Eastern Time (ET). Wedbush PacGrow Healthcare Conference: Zymeworks' management will participate a panel discussion titled "ADCs and Old Lace: Antibody Drug Conjugates" taking place on August 14, between 8:45 – 9:25 am ET, and will participate in one-on-one meetings on August 13-14 in New York, NY. VANCOUVER, British Columbia, July 30, 2024 (GLOBE N ...

VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Leone Patterson as Executive Vice President, and Chief Business and Financial Officer, effective September 1, 2024. "After an extensive search, we are delighted to have Leone Patterson join us at this exciti ...

VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Leone Patterson as Executive Vice President, and Chief Business and Financial Officer, effective September 1, 2024. "I am very pleased to be joining Zymeworks as the Company plans for many important mileston ...

Cautionary Note Regarding Forward-Looking Statements Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looki ...

Zymeworks' development of its product candidates; the timing and status of ongoing and future studies and the related data; expectations and timing regarding future regulatory filings and approvals; the timing of and results of interactions with regulators; potential safety profile and therapeutic effects of zanidatamab and Zymeworks' other product candidates; the commercial potential of technology platforms and product candidates and other information that is not historical information. When used herein, w ...

Contacts: Investor Inquiries: Shrinal Inamdar Director, Investor Relations (604) 678-1388 ir@zymeworks.com investors@zymeworks.com Media Inquiries: Diana Papove Senior Director, Corporate Communications (604) 678-1388 ir@zymeworks.com media@zymeworks.com Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks' mission is to make a meaningful difference in the lives of people impacted by dif ...

VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its second quarter 2024 financial results after market close on August 1, 2024. Following the announcement, management will host a conference call and webcast to discuss financial results and provid ...